XPNPEP2 and Alzheimer disease: Numerous abnormalities of PP2 A have been reported in AD, including among others decreased protein levels of PP2 A, decreased mRNA and protein levels of the catalytic subunit PP2 AC and variable regulatory B subunits and reduced methylation of the catalytic subunit, all of which results in disruption of the PP2 A phosphatase activity.